These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32046620)

  • 21. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbiological and immunologic considerations with aerosolized drug delivery.
    LiPuma JJ
    Chest; 2001 Sep; 120(3 Suppl):118S-123S. PubMed ID: 11555566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
    Geller DE; Weers J; Heuerding S
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):175-82. PubMed ID: 21395432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.
    Elborn JS; Flume PA; Cohen F; Loutit J; VanDevanter DR
    J Cyst Fibros; 2016 Sep; 15(5):634-40. PubMed ID: 26935334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
    Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
    Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
    Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
    J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment.
    Blanchard AC; Rooney AM; Yau Y; Zhang Y; Stapleton PJ; Horton E; Klingel M; Stanojevic S; Ratjen F; Coburn B; Waters V
    J Cyst Fibros; 2018 Nov; 17(6):723-728. PubMed ID: 29525410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Conole D; Keating GM
    Drugs; 2014 Mar; 74(3):377-87. PubMed ID: 24510624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?
    Uttley L; Tappenden P
    Curr Opin Pulm Med; 2014 Nov; 20(6):607-12. PubMed ID: 25221853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis.
    Nolan K; Knight H; Clark P
    Lancet Respir Med; 2013 Apr; 1(2):102-3. PubMed ID: 24429083
    [No Abstract]   [Full Text] [Related]  

  • 32. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
    Mayer-Hamblett N; Rosenfeld M; Treggiari MM; Konstan MW; Retsch-Bogart G; Morgan W; Wagener J; Gibson RL; Khan U; Emerson J; Thompson V; Elkin EP; Ramsey BW; ;
    Pediatr Pulmonol; 2013 Oct; 48(10):943-53. PubMed ID: 23818295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F
    Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of different eradication treatment protocols for new-onset Pseudomonas aeruginosa in children with cystic fibrosis.
    Sunman B; Emiralioglu N; Hazirolan G; Şener B; Ozsezen B; Tural DA; Buyuksahin HN; Guzelkas I; Yalcin E; Dogru D; Özçelik U; Kiper N
    Pediatr Pulmonol; 2022 Jun; 57(6):1456-1465. PubMed ID: 35229497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of tobramycin for Pseudomonas aeruginosa: a review.
    Fiel SB; Roesch EA
    Expert Rev Respir Med; 2022 May; 16(5):503-509. PubMed ID: 35320051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial.
    Puvvadi R; Mikkelsen H; McCahon L; Grogan S; Ditcham W; Reid DW; Lamont I; Stick SM; Clements B
    J Cyst Fibros; 2021 Mar; 20(2):316-323. PubMed ID: 33341406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough.
    Meerburg JJ; Albasri M; van der Wiel EC; Andrinopoulou ER; van der Eerden MM; Majoor CJ; Arets HGM; Heijerman HGM; Tiddens HAWM
    Pediatr Pulmonol; 2019 Nov; 54(11):1794-1800. PubMed ID: 31393073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
    Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
    Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.